Molecular Partners AG is banking CHF55 million (US$60.9 million) up front and could get up to CHF1 billion more in development and commercial milestones, as well as research funding, in a multi-product oncology discovery alliance with Roche Holding AG that marries its Darpin scaffold technology with Roche’s expertise in drug conjugates.
